GlassScriptPhysician profile
Sarah Malik
NPI 1821762121
$5,001.51
in general payments reported to CMS, 2019-2025
20 companies · $2,225 in 2025
The $2,225 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $113 · 2023: $68.70 · 2024: $2,595 · 2025: $2,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,888.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,702.17 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $726.72 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $647.91 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $414.60 | 2023-2025 | Auvelity |
| Alkermes, INC. | $356.78 | 2022-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $214.97 | 2025 | Qelbree |
| Corium, LLC | $144.40 | 2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $139.71 | 2022-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $128.73 | 2022-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $124.78 | 2024 | Nuplazid |
| Lundbeck LLC | $84.98 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $76.59 | 2024-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Janssen Scientific Affairs, LLC | $52.82 | 2024-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $45.67 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $39.45 | 2024 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $22.44 | 2025 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.33 | 2024 | Abilify Maintena, Abilify Asimtufii |
| Antares Pharma, INC. | $21.23 | 2024 | Xyosted |
| Novo Nordisk INC | $19.74 | 2025 | Wegovy |
| Glaxosmithkline, LLC. | $15.49 | 2024 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.